CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/ β-catenin Signaling.

CONCLUSION: CDK12 overexpression promotes breast cancer tumorigenesis and maintains the stemness of breast cancer by activating c-myc/β-catenin signaling. Inhibiting CDK12 expression may become a potential therapy for breast cancer.
PMID: 31744448 [PubMed - as supplied by publisher]

Source: Current Cancer Drug Targets - November 16, 2019 Category: Cancer & Oncology Authors: Peng F, Yang C, Kong Y, Huang X, Chen Y, Zhou Y, Xie X, Liu P Tags: Curr Cancer Drug Targets Source Type: research